Sanofi and Google to develop new healthcare Innovation Lab

SanofiSanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies. The collaboration aims to change how Sanofi develops new treatments and will focus on three key objectives: to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi's patients and customers.

"We stand on the forefront of a new age for biology and human health, with the opportunity to transform healthcare through partnerships with pioneering technology and analytics companies," says Ameet Nathwani, M.D., Chief Digital Officer, Chief Medical Officer & Executive Vice President, Medical at Sanofi. "Combining Sanofi's biologic innovations and scientific data with Google’s industry-leading capabilities, from cloud computing to state-of-the-art artificial intelligence, we aspire to give people more control over their health and accelerate the discovery of new therapies."

"Life sciences companies are looking to data driven, digital innovation to help fuel the creation of accessible healthcare solutions," said Thomas Kurian, CEO, Google Cloud. "We look forward to collaborating with Sanofi to help accelerate the cycle of healthcare innovation to populations throughout the world."

The Innovation Lab will develop both scientific and commercial solutions

Sanofi and Google will leverage deep analytics across data sets to better understand key diseases and extract related patient insights. This will enable Sanofi to research and develop more personalized approaches to treatment and identify accompanying technologies to improve health outcomes. The companies will apply technology and analytics on Sanofi's large real world database to better understand what treatments work for patients. This aims to result in an improved ability to offer personalized treatment advice, thus optimizing patient care and reducing healthcare costs.

Sanofi and Google also plan to apply artificial intelligence (AI) across diverse datasets to better forecast sales and inform marketing and supply chain efforts. Using AI will take into account real-time information as well as geographic, logistic and manufacturing constraints to help the accuracy of these complex activities.

Additionally, Sanofi IT will be modernizing its infrastructure by migrating some existing business applications to Google Cloud Platform (GCP). By leveraging automation, scalability, and agility - along with increases in data and analytic capabilities - Sanofi will accelerate and simplify legacy management, provide easy access to recent technologies and its integration into business plans. The transition to GCP will maximize operational cost efficiency and support business objectives, including the Innovation Lab.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...